Eccentric dosing with isosorbide-5-mononitrate in angina pectoris

In a placebo-controlled, parallel, double-blind study, 214 patients with stable angina were studied. Doses of 5, 10 and 20 mg of immediate-release isosorbide5-mononttrate (IS-S-MN) or placebo were administered at 0800 and 1500 hours for a period of 3 weeks. On days 1 and 14, patients underwent exercise testing before, and 2 and 7 hours after both doses; on days 7 and 21, testing was performed 2 hours after morning dosing. Study variables included total exercise duration and time to moderate angina. On day 1, the active treatment groups showed improvement over the placebo group 2 and 7 hours after dose 1, and 2 hours after dose 2. Throughout the subsequent study period, each active treatment group was superior to placebo 2 hours after the first and second doses. Only the 20 mg dose increased exercise duration 7 hours after dosing, and this was observed after both doses 1 and 2 on day 14. There were fewer episodes of angora in patients receiving the 20 mg dose. There was no increase in nocturnal angina during eccentric dosing with IS5-MN. In comparing exercise times throughout the study, tolerance did not develop during eccentric dosing. The morning exercise tests before tablet administration showed a progressive increase during the study period, with slightly greater improvement in patients receiving active therapy. This absence of a zero hour effect suggests that rebound does not occur during eccentric dosing with immediate-release IS-5-MN.